Snapshot from Jul 19, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / AstraZeneca Wainua trial fails
Business drug trial failure

AstraZeneca Wainua trial fails

Analysis based on 6 articles · First reported Jul 09, 2026 · Last updated Jul 09, 2026

Sentiment
-30
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

AstraZeneca's stock fell 11%, erasing over £20 billion in market capitalization, and dragged the FTSE 100 into negative territory. The failure undermines AstraZeneca's growth pipeline and raises doubts about its 2030 revenue targets.

Pharmaceuticals Biotechnology
Event Summary

AstraZeneca announced that its drug Wainua, developed jointly with Ionis Pharmaceuticals, failed to meet the primary endpoint in a Phase 3 trial for transthyretin-mediated amyloid cardiomyopathy, a progressive heart condition. The trial aimed to reduce cardiovascular mortality and recurrent events when added to standard care. The failure led to an 11% drop in AstraZeneca's stock, wiping out over £20 billion in market value. Analysts noted that the setback threatens AstraZeneca's 2030 revenue targets, as peak annual sales of Wainua were estimated at $6 billion. The news also dragged the FTSE 100 Index lower.

Key Actions
100 AstraZeneca failed trial
100 AstraZeneca lost market value
Entities Involved
stock
AstraZeneca
AstraZeneca suffered a major drug trial failure for Wainua, causing an 11% stock drop and over £20 billion loss in market value, threatening its 2030 revenue goals.
Importance 100.0 Sentiment -80.0
stock
Ionis Pharmaceuticals
Ionis Pharmaceuticals co-developed Wainua with AstraZeneca; the trial failure negatively impacts Ionis's pipeline prospects and partnership value.
Importance 60.0 Sentiment -50.0
index
FTSE 100 Index
The FTSE 100 Index was led into the red by AstraZeneca's sharp decline, reflecting the index's sensitivity to heavyweight pharmaceutical stocks.
Importance 30.0 Sentiment -10.0
per
Sharon Barr
Sharon Barr, AstraZeneca's executive vice president of biopharmaceuticals R&D, commented on the trial results, emphasizing scientific understanding gained despite the failure.
Importance 20.0 Sentiment 0.0
per
Chris Beauchamp
Chris Beauchamp, chief market analyst at IG, provided market commentary highlighting the blow to AstraZeneca's 2030 targets.
Importance 10.0 Sentiment 0.0
per
Neil Wilson
Neil Wilson, Saxo UK investor strategist, noted the setback and estimated peak sales of Wainua at $6 billion.
Importance 10.0 Sentiment 0.0
stock
IG Group
IG Group's analyst Chris Beauchamp offered analysis on the event, but the company itself is not directly affected.
Importance 5.0 Sentiment 0.0
priv
Saxo Bank
Saxo Bank's strategist provided commentary, but the bank itself is not directly impacted.
Importance 5.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.